Data readout expected in the second quarter of 2020 WALTHAM, Mass. , Feb. 05, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies addressing high unmet medical needs in the treatment of central
WALTHAM, Mass. , July 05, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company, today announced the closing of its previously announced public offering of 5,750,000 shares of its common stock, including 750,000 shares sold pursuant to the
Dr. Jay Saoud, Head of Research & Development, to retire from his current role and transition to an advisory role in which he will continue to support the preparation and planned submission of a New Drug Application (NDA) for Minerva’s lead program, roluperidone WALTHAM, Mass. , Sept.
Primary endpoint, defined as Latency to Persistent Sleep (LPS) at Night 1, showed improvement with a p-value ≤0.001 after treatment with 10 and 20 mg doses of seltorexant Key secondary endpoint, defined as Wake After Sleep Onset over first 6 hours (WASO‑6) at Night 1, showed improvement with a
